Reversibility of hepatitis B virus-induced liver cirrhosis after prolonged antiviral therapy;Desaparición de cirrosis hepática por VHB tras tratamiento prolongado con antivirales

Gastroenterologia y Hepatologia

Volumn 33, Issue 7, 2010, Pages 498-503

  Pérez Roldán, Francisco ^a   Vives Domínguez, Leopoldo ^a   González Carro, Pedro ^a   Villafáñez García, Maria Concepción ^a   Fernández Acenero, Maria Jesús ^b   Cuesta Domínguez, Rubén ^a   Aoufi Rabih, Sami ^a   Ruíz Carrillo, Francisco ^a  

^a HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Antiviral therapy; Hepatitis B virus; Reversibility of liver cirrhosis

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; IMMUNOGLOBULIN; LAMIVUDINE; VIRUS DNA;

ADULT; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MEDICAL DOCUMENTATION; SEROLOGY; THROMBOCYTE COUNT;

ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS;

EID: 77956419671     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2010.04.007     Document Type: Article

References (16)

1. Tarantino G, Craxi A. Reversibility of fibrosis. Immunology and the liver: Inflammation, repair and therapies. In: Moreno-Otero R, Albillos A, Bañares R, Cuervas-Mons V, Medina J, editors. Acción Médica SA. Madrid, 2006:201-6.
2. Manning D.S., Afdhal N.H. Diagnosis and quantification of fibrosis. Gastroenterology 2008, 134:1670-1681.
3. Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:95-107.
4. Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008, 12:939-962.
5. Serpaggi J., Carnot F., Nalpas B., Canioni D., Guéchot J., Lebray P., et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006, 37:1519-1526.
6. Farrell G.C., Teoh N.C. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006, 36:100-113.
7. Planas R., Morillas R.M. Treatment of hepatitis B virus infection: present and future. Gastroenterol Hepatol 2008, 31:349-355.
8. Sánchez-Tapias J.M. Pharmacological agents for the treatment of chronic hepatitis B. Gastroenterol Hepatol 2008, 31:120-128.
9. Bortolotti F., Guido M. Reversal of liver cirrosis: a desirable clinical outcome and its pathogenic background. J Pediatr Gastroenterol Nutr 2007, 44:401-406.
10. Mallet V.O., Dhalluin-Venier V., Verkarre V., Correas J.M., Chaix M.L., Virad J.P., et al. Reversibility of cirrosis in HIV/HBV coinfection. Antivir Ther 2007, 12:279-283.
11. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Gardner S., et al. Histological outcome during long-term lamivudina therapy. Gastroenterology 2003, 124:105-117.
12. Pohl A., Behling C., Oliver D., Kilani M., Monson P., Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001, 96:3142-3146.
13. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
14. Desmet V.J., Roskams T. Reversal of cirrhosis: Evidence-based Medicine?. Gastroenterology 2003, 125:629-630.
15. Suzuki Y., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Hosaka T., et al. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?. J Gastroenterol Hepatol 2009, 24:429-435.
16. Van Zonneveld M., Zondervan P.E., Cakaloglu Y., Simon C., Akarca U.S., So T.M., et al. Peg-interferon improves liver histology in patients with HbeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudina. Liver Int 2006, 26:399-405. HBV 99-01 Study Group.